Clinical statistics of gynecologic cancers in Japan

Abstract

Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)

“…The ratio of histologic types differs between Japan, Europe, and North America, with a lower prevalence of high-grade serous carcinoma in Japanese populations than in Caucasians, which might have affected the prevalence of g BRCA mutations 18. However, we should note that in the present study the prevalence of g BRCA1/2 mutations in patients with high-grade serous carcinoma was slightly higher (28.5%) than that reported in previous studies 8 19.…”

Establishment and characterization of patient‐derived organoids from a young patient with cervical clear cell carcinoma

“…Consequently, it could help investigations on the mechanisms underlying the early phase of carcinogenesis of cCCC, and recapitulation of tumor progression by gene transduction into organoids. Given the low number of studies with cCCC, we referred to studies in ovarian CCC, which is the second most common ovarian epithelial cancer in Japan . For example, chromosomal gains and losses identified in cCCC resembled those of ovarian CCC previously documented .…”

“…Cervical cancer has been a global threat to women's health. More than two‐thirds of cervical cancers are classified as squamous cell carcinoma, which is currently decreasing owing to intensive cervical screening and vaccination against HPV. The remainder are predominantly adenocarcinoma, which is on the rise worldwide, requiring prompt and practical measures against this disease.…”

Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases

“…4 While most cases are diagnosed at an early stage (stage I), stage II disease represents approximately 6% of all ECs. 5 Stage II EC is usually treated with either extrafascial or radical hysterectomy. Radical hysterectomy has been recommended for patients with stage II EC because up to 13% of patients with EC have parametrial involvement.…”